Meta-Analysis Finds Increased Risk of MI with Rosiglitazone (Avandia)

MedPageToday has just reported that a meta-analysis of 42 randomized trials released online by the New England Journal of Medicine found a 43 percent increase in the risk of myocardial infarction among type 2 diabetics treated with rosiglitazone (Avandia), although the absolute number of events was small.

According to MedPage, a journal editorial says FDA action is warranted, and a congressional inquiry is expected.

If you or a loved one has suffered cardiac complications after ingesting Avandia, you deserve the guidance of a knowledgeable drug attorney. Get a free case review by filling out the form below.

Click To Talk To Us Online

Study, 7.12.07

Latest News on Avandia: German Study Adds More Reasons to Avoid it
Latest Study in the News: Avandia May Worsen Complications of Diabetes

Avandia Panel, 7.25.07

Academic Panel of Scientists to Meet With FDA Regarding Avandia Risks
Scientific Panel to Advise FDA on Avandia Heart Attack Risk

Name

Phone

strictly confidential

Your Question

Contact Name
Email Address
Phone Number
When did you start taking Avandia?
Did you experience cardiovascular problems after taking Avandia?
What was the date you experienced cardiac complications?
Did you have any cardiovascular disease before taking Avandia?
Did you suffer a bone fracture after taking either Avandia or Actos?
Please provide detail about your bone fracture injury, including the date of the injury, how the fracture occured and what bone(s) were affected.
Additional information